Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Darius Armstrong-James; Jonathan Youngs; Tihana Bicanic; Alireza Abdolrasouli; David W Denning; Elizabeth Johnson; Varun Mehra; Tony Pagliuca; Brijesh Patel; Johanna Rhodes; Silke Schelenz; Anand Shah; Frank L van de Veerdonk; Paul E Verweij; P Lewis White; Matthew C Fisher

doi:10.1183/13993003.02554-2020

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Eur Respir J. 2020 Oct 1;56(4):2002554. doi: 10.1183/13993003.02554-2020. Print 2020 Oct.

Authors

Darius Armstrong-James^{1

2}, Jonathan Youngs³, Tihana Bicanic³, Alireza Abdolrasouli⁴, David W Denning⁵, Elizabeth Johnson⁶, Varun Mehra⁷, Tony Pagliuca⁷, Brijesh Patel⁸, Johanna Rhodes⁹, Silke Schelenz¹⁰, Anand Shah^{9

11}, Frank L van de Veerdonk¹², Paul E Verweij¹², P Lewis White¹³, Matthew C Fisher^{9

2}

Affiliations

¹ Dept of Infectious Diseases, Imperial College London, London, UK d.armstrong@imperial.ac.uk.
² D. Armstrong-James and Matthew C. Fisher contributed equally to this article as lead authors and supervised the work.
³ Institute of Infection and Immunity, St George's University of London, London, UK.
⁴ Dept of Medical Microbiology, North West London Pathology, Imperial College Healthcare NHS Trust, London, UK.
⁵ Faculty of Biology, Medicine and Health, The University of Manchester, National Aspergillosis Centre, Wythenshawe Hospital and Manchester Academic Health Science Centre, Manchester, UK.
⁶ Mycology Reference Laboratory, Public Health England National Infection Service, Bristol, UK.
⁷ Dept of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK.
⁸ Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
⁹ MRC Center for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
¹⁰ Infection Sciences, Kings College Hospital NHS Foundation Trust, London, UK.
¹¹ Royal Brompton and Harefield NHS Foundation Trust, London, UK.
¹² Dept of Medical Microbiology and Centre of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre, Nijmegen, The Netherlands.
¹³ Mycology Reference Laboratory, Public Health Wales Microbiology Cardiff, Cardiff, UK.

Abstract

Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections https://bit.ly/3feuGsQ

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antifungal Agents / therapeutic use
Betacoronavirus
Bronchoalveolar Lavage Fluid / microbiology
Bronchoscopy
COVID-19
COVID-19 Drug Treatment
Coinfection / diagnosis
Coinfection / drug therapy
Coinfection / epidemiology
Coronavirus Infections / drug therapy
Coronavirus Infections / epidemiology*
Humans
Immunologic Factors / therapeutic use
Intensive Care Units
Invasive Pulmonary Aspergillosis / diagnosis
Invasive Pulmonary Aspergillosis / drug therapy
Invasive Pulmonary Aspergillosis / epidemiology
Pandemics
Pneumonia, Viral / drug therapy
Pneumonia, Viral / epidemiology*
Pulmonary Aspergillosis / diagnosis
Pulmonary Aspergillosis / drug therapy
Pulmonary Aspergillosis / epidemiology*
Risk Factors
SARS-CoV-2
Ventilation

Substances

Adrenal Cortex Hormones
Antifungal Agents
Immunologic Factors

Abstract

Publication types

MeSH terms

Substances

Grants and funding